U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07579884) titled 'To Evaluate the Safety and Efficacy of RP902 Tablets' on April 22.
Brief Summary: The purpose of the study is to evaluate the preliminary efficacy of RP902 Tablets in participants with Alzheimer's disease (AD)-derived mild cognitive impairment (MCI) and provide a design basis for the Phase III study. This Phase II study plans to enroll 360 participants and will be conducted at approximately 50 sites in China. The study consists of a Screening Period (up to 4 weeks) and a double-blind treatment period (48 weeks). After completing the 48-week double-blind treatment period, participants may choose to continue into an extension treatment...